# TLR4 in the Regulation of Renal Microvascular Function

> **NIH NIH R01** · UNIVERSITY OF ALABAMA AT BIRMINGHAM · 2021 · $507,126

## Abstract

Project Summary:
Hypertension, a major risk factor for cardiovascular disease among US citizens and causes significant endo
organ damage due to inflammation, and tissue injury. Exquisite autoregulatory control of renal vascular
resistance is essential to protect against hyperbaric trauma and glomerular injury. Loss of autoregulatory
control, as occurs in hypertension, increases glomerular capillary pressure and promotes renal injury.
Hypertension activates inflammatory cascades that sustain the hypertensive state and accelerate renal injury
progression. Anti-inflammatory treatment prevents autoregulatory impairment but a critical barrier to progress
with hypertensive renal injury is identification of the inflammatory mechanisms involved. We now provide
compelling new evidence identifying toll-like receptor 4 (TLR4) and major histocompatibility complex class II
(MHC-II) molecules as mechanistic links between inflammation and autoregulatory dysfunction. The studies
proposed address the central hypothesis the TLR4 on renal microvascular cells and on resident MHC-II
bearing cells is activated in hypertension, leading to afferent arteriole autoregulatory dysfunction and kidney
injury. Aim 1 will test the hypothesis that chronic TLR4 activation with low dose LPS treatment blunts afferent
arteriole autoregulatory behavior. We will use the blood-perfused juxtamedullary nephron preparation to
investigate the role of TLR4 signaling on autoregulatory function. Chronic administration of the TLR4 agonist,
LPS, anti-TLR4 antibodies or TLR4 antagonists will reveal the role of TLR4 in intact renal microvessels of
normotensive rats. Aim 2 will test the hypothesis that AngII hypertension blunts autoregulatory behavior
through mechanisms linked to TLR4 activation. Autoregulatory behavior will be assessed in vitro and in vivo in
AngII-infused hypertensive rats with and without chronic administration of LPS, anti-TLR4 antibody or a TLR4
antagonist to establish the role of TLR4 in the renal microvascular dysfunction that occurs in AngII
hypertension. Aim 3 will test the hypothesis that TLR4-mediated loss of autoregulation in AngII hypertension
is prevented by targeting MHC-II. A novel CLIP antagonist that ameliorates TLR4-mediated loss of
autoregulation will test the efficacy of targeting MHC-II in AngII hypertension. Upon completion of these
aims, we will have established that chronic TLR4 activation leads to a decline in renal microvascular
autoregulatory capability and that this process is linked to MHC-II immune activation. We further expect
that TLR4 activation underlies the renal autoregulatory dysfunction in AngII-induced hypertension through
this MHC-II mechanism and contributes to hypertensive renal injury.

## Key facts

- **NIH application ID:** 10146343
- **Project number:** 5R01DK044628-24
- **Recipient organization:** UNIVERSITY OF ALABAMA AT BIRMINGHAM
- **Principal Investigator:** Edward W Inscho
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $507,126
- **Award type:** 5
- **Project period:** 1994-08-01 → 2023-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10146343

## Citation

> US National Institutes of Health, RePORTER application 10146343, TLR4 in the Regulation of Renal Microvascular Function (5R01DK044628-24). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10146343. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*